Brief Title
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
Official Title
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
Brief Summary
The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation. For this the investigators want to assay the insulin resistance marker Insulin Regulated Amino Peptidase serique (IRAPs), the plasma lipidome and inflammation markers in 2 populations of insulin-resistant subjects due to Dunnigan's inherited lipodystrophy or overweight/obesity and insulin-sensitive subjects with or without a glycemic regulation disorder objectified during an Oral induced hyperglycemia. The results of the IRAPs, lipidome and inflammation assays will be compared in insulin-resistant subjects, between normoglycemic, prediabetic and diabetic subjects. Correlations will be made between these markers and the deterioration of glycemic regulation as well as with known insulin resistance parameters (HOmeostasis Assessment Model (HOMA), Quantitative Insulin-sensitivity Check Index (QUICKI),Insulin Sensitivity Index (Isi) MATSUDA).
Study Type
Interventional
Primary Outcome
Insulin Regulated Amino Peptidase sérique (IRAPs) levels
Secondary Outcome
Compare levels of Insulin Regulated Amino Peptidase sérique (IRAPs) between the 3 categories of participants
Condition
Lipodystrophy
Intervention
research-specific blood sample
Study Arms / Comparison Groups
Subjects with Dunnigan's Lipodystrophy
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
210
Start Date
August 17, 2021
Completion Date
December 2024
Primary Completion Date
August 2024
Eligibility Criteria
Inclusion Criteria: - Subjects with Dunnigan's Lipodystrophy OR Non-lipodystrophic insulin-resistant subjects OR Insulin-sensitive non-lipodystrophic subjects - major - Subjects benefiting from metabolic exploration in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital. - Subject benefiting from an oral glucose tolerance test (OGTT) during his follow-up in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital. - Person affiliated or beneficiary of a social security scheme. - Subject having been informed of the study in progress and having given their written consent. Exclusion Criteria: - Pregnant woman - Person under guardianship or curators or deprived of liberty
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, 02 62 35 97 50, [email protected]
Location Countries
Réunion
Location Countries
Réunion
Administrative Informations
NCT ID
NCT05424913
Organization ID
2017/CHU/07-2021-A00105-36
Responsible Party
Sponsor
Study Sponsor
Centre Hospitalier Universitaire de la Réunion
Study Sponsor
, ,
Verification Date
June 2022